KR970706828A - 경피 투여형 제제(percutaneously administrable preparation) - Google Patents
경피 투여형 제제(percutaneously administrable preparation)Info
- Publication number
- KR970706828A KR970706828A KR1019970702648A KR19970702648A KR970706828A KR 970706828 A KR970706828 A KR 970706828A KR 1019970702648 A KR1019970702648 A KR 1019970702648A KR 19970702648 A KR19970702648 A KR 19970702648A KR 970706828 A KR970706828 A KR 970706828A
- Authority
- KR
- South Korea
- Prior art keywords
- transdermal
- fatty acid
- transdermal patch
- patch according
- absorption enhancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
활성성분으로서 9-아미노-시클로펜타(b)퀴놀린, 바람직하게는 9-아미노-2,3,5,6,7,8-헥사히드로-1H-시클로펜타(b)퀴놀린 또는 그의 염산염과 다음의 경피 흡수촉진제, 즉 지방산, 지방산 에스테르 및 알코올 바람직하게는 6-12개의 탄소 원자를 가진 포화지방산의 글리세라이드 중에서 선택된 최소한 1가지 화합물을 함유하는 경피투여형제제.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (13)
- 활성성분으로서 9-아미노시클로펜타(b)퀴놀린 경피흡수촉진제로 구성된 것이 특징인 경피투여형제제.
- 제1항에 있어서, 활성성분이 9-아미노-2,3,5,6,7,8-헥사히드로-1H-시클로펜타(b)퀴놀린 또는 그의 약리학적으로 허용되는 염인 것이 특징인 경피투여형제제.
- 제1항 또는 제2항에 있어서, 활성성분이 9-아미노-2,3,5,6,7,8-헥사히드로-1H-시클로펜타(b)퀴놀린 염산염 1수화물인 것이 특징인 경피투여형제제.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 경피흡수촉진제가 지방산, 지방산 에스테르 및 알코올류로 구성되는 군에서 선택된 최소한 1가지 화합물인 것이 특징인 경피투여형제제.
- 제4항에 있어서, 경피흡수촉진제가 지방산인 것이 특징인 경피투여형제제.
- 제5항에 있어서, 지방산이 12-18개의 탄소원자를 가진 포화 또는 불포화지방산인 것이 특징인 경피투여형제제.
- 제4항에 있어서, 경피흡수촉진제가 지방산에스테르인 것이 특징인 경피투여형제제.
- 제7항에 있어서, 지방산 에스테르가 중간사슬 지방산의 글리세라이드인 것이 특징인 경피투여형제제.
- 제8항에 있어서, 중간사슬 지방산의 글리세라이드가 6-12개의 탄소원자를 가진 포화지방산의 모노 글리세라이드인 것이 특징인 경피투여형제제.
- 제4항에 있어서, 경피흡수촉진제가 알코올인 것이 특징인 경피투여형제제.
- 제10항에 있어서, 알코올이 4-12개의 탄소원자를 가진 포화 또는 불포화 알코올인 것이 특징인 경피투여형제제.
- 제1항 내지 제11항 중 어느 한 항에 있어서, 경피투여형제제가 연고제, 크림제, 겔제와 찜질제제중의 어느 하나인 것이 특징인 경피투여형제제.
- 제1항 내지 제11항 중 어느 한 항에 있어서, 경피투여형제제가 테이프 또는 패치제제인 것이 특징인 경피투여형제제.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP28246794 | 1994-10-24 | ||
JP282467/1994 | 1994-10-24 | ||
PCT/JP1995/002183 WO1996012495A1 (fr) | 1994-10-24 | 1995-10-24 | Preparation administrable par voie percutanee |
Publications (2)
Publication Number | Publication Date |
---|---|
KR970706828A true KR970706828A (ko) | 1997-12-01 |
KR100192149B1 KR100192149B1 (ko) | 1999-06-15 |
Family
ID=17652814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019970702648A KR100192149B1 (ko) | 1994-10-24 | 1995-10-24 | 경피 투여형 제제 |
Country Status (7)
Country | Link |
---|---|
US (1) | US5869088A (ko) |
EP (1) | EP0793963A4 (ko) |
KR (1) | KR100192149B1 (ko) |
CA (1) | CA2203566C (ko) |
FI (1) | FI971752A (ko) |
NO (1) | NO971879L (ko) |
WO (1) | WO1996012495A1 (ko) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6193993B1 (en) * | 1998-03-03 | 2001-02-27 | Eisai Co., Ltd. | Suppository containing an antidementia medicament |
JP3987655B2 (ja) * | 1998-03-03 | 2007-10-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗痴呆薬を含有した経皮適用製剤又は坐剤 |
NZ513441A (en) * | 1999-02-08 | 2004-01-30 | Alza Corp | Stable non-aqueous single phase viscous drug delivery vehicles comprising a polymer a solvent and a surfactant |
PT1362600E (pt) * | 2001-02-20 | 2008-07-09 | Anges Mg Inc | Utilização tópica de iscos de nf-kb para o tratamento da dermatite atópica |
US6479060B1 (en) | 2001-09-04 | 2002-11-12 | Healthpoint, Ltd. | Elegant hydrogenated castor oil ointments |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4550113A (en) * | 1982-08-19 | 1985-10-29 | Nauchno-Issledovatelsky Institut Po Biologicheskikm Ispytaniyam Khimicheskikh Soedineny | 9-Amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)quinoline monohydrate hydrochloride as stimulant of neuro-muscular transmission of smooth muscles |
JPS5955830A (ja) * | 1982-09-16 | 1984-03-31 | ナウチノ−イスレドワ−チエルスキ−・インスチツ−ト・ポ・ビオロギチエスキム・イスピタニアム・ヒミチエスキフ・ソエデイネヌイ | 末梢神経系統における興奮伝導の刺戟剤としての医薬組成物 |
RU2057531C1 (ru) * | 1986-07-01 | 1996-04-10 | Всероссийский научный центр по безопасности биологически активных веществ | Средство для стимуляции обучения и памяти |
US5019395A (en) * | 1988-03-08 | 1991-05-28 | Warner-Lambert Company | Compositions with enhanced penetration |
IE62871B1 (en) * | 1988-03-08 | 1995-03-08 | Warner Lambert Co | Compositions with enhanced penetration |
JPH0489429A (ja) * | 1990-07-27 | 1992-03-23 | Fujisawa Pharmaceut Co Ltd | 経皮吸収用製剤 |
JPH06247846A (ja) * | 1993-02-22 | 1994-09-06 | Toko Yakuhin Kogyo Kk | 塩酸リトドリンの経皮吸収製剤用組成物 |
US5629007A (en) * | 1995-03-21 | 1997-05-13 | Eli Lilly And Company | Method of preventing prostatic cancer development |
-
1995
- 1995-10-24 KR KR1019970702648A patent/KR100192149B1/ko not_active IP Right Cessation
- 1995-10-24 US US08/817,510 patent/US5869088A/en not_active Expired - Fee Related
- 1995-10-24 WO PCT/JP1995/002183 patent/WO1996012495A1/ja not_active Application Discontinuation
- 1995-10-24 EP EP95934879A patent/EP0793963A4/en not_active Withdrawn
- 1995-10-24 CA CA002203566A patent/CA2203566C/en not_active Expired - Fee Related
-
1997
- 1997-04-23 NO NO971879A patent/NO971879L/no not_active Application Discontinuation
- 1997-04-24 FI FI971752A patent/FI971752A/fi unknown
Also Published As
Publication number | Publication date |
---|---|
EP0793963A1 (en) | 1997-09-10 |
US5869088A (en) | 1999-02-09 |
NO971879L (no) | 1997-06-23 |
EP0793963A4 (en) | 2001-12-12 |
KR100192149B1 (ko) | 1999-06-15 |
WO1996012495A1 (fr) | 1996-05-02 |
FI971752A0 (fi) | 1997-04-24 |
FI971752A (fi) | 1997-04-24 |
NO971879D0 (no) | 1997-04-23 |
CA2203566C (en) | 2001-10-23 |
CA2203566A1 (en) | 1996-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2309178A1 (en) | Topical compositions for nsai drug delivery | |
NZ330369A (en) | aqueous medicaments containing 9-hydroxy-risperidone fatty acid ester | |
IE940583L (en) | Topical antimicrobial pharmaceutical compositions | |
EA199700267A1 (ru) | Применение фумагиллола и его производных для приготовления антиинфекционных интестинальных препаратов и фармацевтическая композиция на их основе | |
CA2190485A1 (en) | Lacrimal gland specific emulsions for topical application to ocular tissue | |
KR910000101A (ko) | 효소형성 억제제 | |
DE60205633D1 (de) | Orale pharmazeutische zusammensetzung mit einem wirkstoff, der bei seiner ersten darmpassage starken wirkungen ausgesetzt werden kann | |
KR930007444A (ko) | 4-비페닐아세트 산(bpaa)를 함유하는 제약학적 조성물 | |
US5438067A (en) | Medetomidine preparations for transdermal administration | |
DE60038097D1 (de) | Feste orale dosierungsform enthaltend einen resorptionsverstärker | |
EP1990061A3 (fr) | Composition pharmaceutique pour administration transdermique ou transmuqueuse | |
KR970703758A (ko) | 피부질환 치료용 외용제(external preparations for treating dermatoses) | |
PT742011E (pt) | Preparacao que pode ser absorvida por via percutanea | |
MY101536A (en) | Anti-inflammatory and analgesic tape for external use | |
US5747069A (en) | Percutaneously absorbable preparation | |
EP0827741A3 (en) | Composition for transdermal delivery system containing nonsteroidal anti-inflammatory drug as an active ingredient | |
BR0009765B1 (pt) | Compostos de ésteres de l-carnitina ou alcanoil l-carnitinase, uso dos mesmos, lipossomas contendo os referidos compostos e composições farmacêuticas e cosméticas contendo os ditos lipossomas. | |
KR950000142A (ko) | 피부질환치료용 약제조성물 제조에 사용되는 히드록시산함유 l-카르니틴에스테르 및 아실 l-카르니틴에스테르의 용도 | |
KR970706828A (ko) | 경피 투여형 제제(percutaneously administrable preparation) | |
WO1999037275A3 (de) | KOSMETISCHE ODER PHARMAZEUTISCHE ZUBEREITUNGEN MIT VERMINDERTEM KLEBRIGKEITSGEFÜHL, ENTHALTEND GLYCERINESTER VON α-HYDROXYCARBONSÄUREN UND GESÄTTIGTEN FETTSÄUREN | |
KR950703941A (ko) | 일산화질소 합성 억제제(nitrogen monoxide synthesis inhibitor) | |
KR930702965A (ko) | 생체이용성이 개선된 프로부콜 함유 제약 조성물 | |
KR970707091A (ko) | 스핑고이드 염기의 레티노일아미드계 유도체(retinoylamide based derivatives of sphingoid bases) | |
SE8705064L (sv) | Emulsion foer parenteral administrering | |
IE802606L (en) | Pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20011206 Year of fee payment: 4 |
|
LAPS | Lapse due to unpaid annual fee |